Mirvie RNA Platform Predicts Severe Fetal Growth Restriction Months Before Birth
The Mirvie RNA platform identified a unique molecular signature predictive of severe fetal growth restriction, allowing early detection.
Read MorePosted by Andy Lundin | Jan 30, 2025 | Womens Health |
The Mirvie RNA platform identified a unique molecular signature predictive of severe fetal growth restriction, allowing early detection.
Read MorePosted by Andy Lundin | Jan 29, 2025 | Cardiovascular, Immunoassay |
Roche’s Tina-quant Lp(a) Gen.2 Molarity assay received FDA 510(k) clearance, supporting more precise cardiovascular risk assessment.
Read MorePosted by Andy Lundin | Jan 28, 2025 | Cancer |
The video-reporting service for in-vitro chemosensitivity testing uses real-time visual evidence to assess chemotherapy drug effectiveness.
Read MorePosted by Andy Lundin | Jan 24, 2025 | Sequencing Systems |
Researchers demonstrate the potential of long-read sequencing to diagnose rare genetic diseases faster and more accurately.
Read MorePosted by Andy Lundin | Jan 21, 2025 | Prostate |
A review found gaps remain for genomic classifier tests for their cost-effectiveness, clinical utility, and impact on diverse populations.
Read More